Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

rea. The Company is evaluating its facility options and should it not locate suitable replacement premises or make alternative arrangements on a timely basis, portions of the Company's operations may be interrupted.

FINANCIAL RESULTS

For the three months ended July 31, 2007 ("Q1/08"), MIGENIX incurred a loss of $3.1 million or $0.03 per common share, compared to a loss of $2.5 million or $0.03 for the three months ended July 31, 2006 ("Q1/07"). The increase in the Q1/08 loss compared to the Q1/07 loss is principally attributable to: (i) a $0.4 million increase in research and development expenses (see "Research and Development" below); (ii) a $0.2 million increase in general and corporate expenses (see "General and Corporate" below; (iii) a $0.1 million increase in the accretion of the convertible royalty participation units (see "Other Income and Expenses" below); less: (iv) a $0.1 million decrease in amortization expense (see "Amortization" below).

Revenues

During Q1/08 the Company had nominal (< $0.1 million) research and development collaboration revenue (Q1/07: $nil). This research and development collaboration revenue is pursuant to the sale of omiganan drug substance to Cutanea Life Sciences.

Research and Development Expenses

The following table summarizes our research and development expenses for the periods indicated:

Three months Financial years

ended July 31 ended April 30

2007 2006 2007 2006

Program Expenses Canadian dollars, millions

Omiganan 1% gel (partnered) 0.0 0.0 0.0 0.0

Omiganan for dermatological

diseases (partnered) 0.0 0.0 0.0 0.0

Celgosivir 0.4 0.4 1.5 2.1

MX-2401
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 ... announced that a team from Iowa State University won ... design contest. Using a Convey HC-2ex, the team’s solution ... 14 times faster than the second place finisher. , ... world embarked upon the month long challenge, using a ...
(Date:10/20/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four ... million and provides a good start to Q4.  The orders are ... and one in the Middle East . ... said Peter Bruijns , President & CEO. "Total bidding activity ... they have been for any complete year since the company has ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... entity to deal with for regulators. , ,In an editorial ... it, I observed that consolidation just like in the ... evolution and is critical for survival: , As a country, ... "revestiture". Revestiture is the industry's modern attempt to circle the ...
... LLC , a software company in Waukesha that sells home ... programs, said on Thursday it has been acquired by a ... it would expand its offerings to manufacturers and retailers by ... and product pictures. Big Hammer operates one of 11 authorized ...
... water main break Thursday at the Milwaukee County Grounds ... 37 companies in the Milwaukee County Research Parks Technology ... businesses in the incubator building were functioning despite the ... in the 137,000-square-foot Technology Innovation Center, said the center ...
Cached Biology Technology:Old bell system merging back together, but it's not the same 2Old bell system merging back together, but it's not the same 3Old bell system merging back together, but it's not the same 4
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... how the bowel lining develops and, in the process, ... , The researchers produced evidence that stem cells are ... a feature of the bowel lining, and believe these ... controversial finding as scientists are still divided on the ... Chin Wee Tan and Professor Tony Burgess from the ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... made concerning the possible inventory of molecules available ... Pizzarello, a research professor at Arizona State University, ... in a blazing fireball over California last year, ... meteorites. These findings suggest a far greater availability ...
... R.I. [Brown University] Although preeclampsia occurs in about ... cases. A report of new research, now in press ... how two distinct risk factors combine to affect the ... life-threatening pregnancy complication. The findings suggest there could be ...
... engineering capabilities that underpin the nuclear weapons stockpile stewardship ... laboratories are "healthy and vibrant," says a new report ... wrote the report found no problems with the quality ... the stockpile. However, the report identifies several issues that, ...
Cached Biology News:ASU scientists strike scientific gold with meteorite 2Study details paired risk factors in preeclampsia 2Study details paired risk factors in preeclampsia 3New report reviews science and engineering quality at national security laboratories 2
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Antibody Diluent for IHC 125 ml...
Biology Products: